O'Brien Laramy Matthew N, Nagapudi Karthik
Small Molecule Pharmaceutical Sciences, Genentech Inc, South San Francisco, CA, USA.
Expert Opin Drug Deliv. 2022 Oct;19(10):1285-1301. doi: 10.1080/17425247.2022.2108397. Epub 2022 Aug 10.
Ocular long-acting injectables and implants (LAIIs) deliver drug at a controlled release rate over weeks to years. A reduced dose frequency eases the treatment burden on patients, minimizes the potential for treatment-related adverse effects, and improves treatment adherence and persistence.
This review provides a comprehensive landscape of ocular LAII drug delivery technologies with clinical precedent, including eight commercial products and 27 clinical programs. Analysis of this landscape, and the specific technologies with the greatest precedent, provides instructive lessons for researchers interested in this space and insights into the direction of the field.
Further technological advancement is required to create biodegradable LAIIs with extended release durations and LAIIs that are compatible with a broader array of therapeutic modalities. In the future, ocular LAII innovations can be applied to diseases with limited treatment options, prophylactic treatment at earlier stages of disease, and cost-effective treatment of ocular diseases in global health settings.
眼部长效注射剂和植入物（LAIIs）可在数周甚至数年的时间内以可控的速率释放药物。给药频率的降低减轻了患者的治疗负担，将治疗相关不良反应的可能性降至最低，并提高了治疗的依从性和持续性。
本综述全面介绍了具有临床先例的眼部LAII药物递送技术，包括8种商业产品和27个临床项目。对这一领域以及具有最大先例的特定技术进行分析，为该领域的研究人员提供了有益的经验教训，并洞察了该领域的发展方向。
需要进一步的技术进步来开发具有更长释放持续时间的可生物降解LAIIs以及与更广泛治疗方式兼容的LAIIs。未来，眼部LAII创新可应用于治疗选择有限的疾病、疾病早期的预防性治疗以及全球卫生环境中眼部疾病的经济有效治疗。
